Neuroderm Ltd. (NDRM) 13.61 $NDRM
NeuroDerm net loss improves in Q4 and FY14
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 6:39AM CDT
NDRM: 13.61 (-0.14)
NeuroDerm reports Q4 results
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 6:05AM CDT
NDRM: 13.61 (-0.14)
NeuroDerm Announces Fourth Quarter and 2014 Fiscal Year Financial Results and Provides a Corporate Update
GlobeNewswire - Thu Apr 02, 6:00AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.
NDRM: 13.61 (-0.14)
NeuroDerm to Announce Updated Topline Results of Phase II Study of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease at the 67th Annual Meeting of the American Academy of Neurology
GlobeNewswire - Wed Apr 01, 6:00AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that updated results from the Phase II Study assessing the safety, tolerability and pharmacokinetics (PK) of ND0612L will be presented at the American Academy of Neurology (AAN) 67 Annual Meeting taking place April 18 to 25, 2015 in Washington, DC.
NDRM: 13.61 (-0.14)
New Parkinson's drug cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 9:23AM CST
ADMS: 17.70 (-0.03), ACOR: 33.12 (-0.38), NDRM: 13.61 (-0.14), XNPT: 7.36 (-0.14), IPXL: 49.55 (-0.53), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), PRTA: 37.35 (-0.48)
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 49.55 (-0.53), ADMS: 17.70 (-0.03), ACOR: 33.12 (-0.38), NDRM: 13.61 (-0.14)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 11:46AM CST
HTBX: 6.89 (-0.71), NES: 3.80 (-0.07), TEAR: 2.44 (-0.02), FENG: 7.27 (+0.02), OCN: 7.74 (-0.15), STX: 58.34 (-0.41), LACO: 8.70 (unch), PHMD: 2.05 (+0.09), BBEP: 6.23 (-0.06), HGSH: 3.28 (+0.05), MBT: 11.97 (+0.18), NBG: 1.23 (+0.06), NDRM: 13.61 (-0.14), PT: 0.66 (-0.03), POST: 47.60 (-0.58), ATNM: 2.95 (-0.08), MWV: 47.50 (+0.41), WRES: 1.14 (-0.02), IDN: 1.63 (unch), KONE: 5.49 (+0.86)
NeuroDerm Announces Extraordinary General Meeting of Shareholders for Ratification of Election of External Directors and Adoption of Compensation Policy
GlobeNewswire - Mon Jan 19, 10:15AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will hold an Extraordinary General Meeting of Shareholders on Monday, February 23, 2015 for the purposes of ratifying the election of the Company's external directors, Alla Felder and Jonathan Kalman, and adopting a compensation policy for the Company's executives and directors. The record date for shareholders entitled to vote at the meeting is Friday, January 23, 2015.
NDRM: 13.61 (-0.14)
Securities Lending Notable Names: JCP, AMBA
Interactive Brokers - at Seeking Alpha - Tue Jan 13, 2:32AM CST
Strong sales guidance gave some life to struggling department store operator, J.C. Penney Co., Inc. (NYSE: JCP ) last week following a prolonged period of negative news. The stock soared approximately 17% on Tuesday of last week after the company...
AMBA: 72.13 (-1.32), GPRO: 44.73 (-1.35), EDAP: 3.30 (-0.07), LNCO: 12.13 (-0.24), IMRS: 0.69 (+0.04), GALT: 3.29 (-0.04), JCP: 8.41 (-0.07), MOC: 1.92 (+0.02), BIND: 6.84 (-0.33), LINE: 13.56 (-0.05), JOB: 0.83 (+0.01), BCLI: 4.14 (+0.02), NDRM: 13.61 (-0.14)
NeuroDerm Ltd. (NDRM) in Focus: Stock Surges 13.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 8:11AM CST
NeuroDerm Ltd. (NDRM) was a big mover last session, as the company saw its shares rise over 13% on the day.
BIOD: 1.14 (-0.13), NDRM: 13.61 (-0.14)
NeuroDerm (NDRM) in Focus: Stock Tanks 22.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 7:40AM CST
Make sure to keep a close watch on NeuroDerm in the near future, and especially on earnings estimates following the recent slump.
NDRM: 13.61 (-0.14)
NeuroDerm set for modest gap up at the open
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 7:38AM CST
NDRM: 13.61 (-0.14)
NeuroDerm Skyrockets on Parkinson's Disease Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 2:50PM CST
NeuroDerm (NDRM) announced encouraging top-line data from a phase IIa pharmacokinetic study on its levodopa/carbidopa candidates, ND0612H and ND0612L.
IPXL: 49.55 (-0.53), ABBV: 66.07 (+1.82), NDRM: 13.61 (-0.14), NVS: 104.28 (-1.22)
Market News: Civeo Corp, Eagle Rock Energy Partners, Neuderm Ltd
at The Street - Wed Dec 31, 1:53PM CST
The stock markets in the United States fluctuated declined, wiping out earlier gains today–the last trading session for 2014. The markets were negatively impacted by the weakness of equities in ...
CVEO: 3.43 (-0.06), EROC: 2.55 (+0.03), NDRM: 13.61 (-0.14)
NeuroDerm (NDRM) Stock Plunges Today Following Tuesday's Gains
at The Street - Wed Dec 31, 1:16PM CST
Shares of NeuroDerm (NDRM) plummeted Wednesday as the stock sold off one day after it soared following the company's announcement of encouraging trial results for a treatment of Parkinson's disease.
NDRM: 13.61 (-0.14)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 8:15AM CST
CYTK: 7.25 (-0.18), NEON: 4.56 (-0.16), ARWR: 7.28 (+0.05), NRX: 8.26 (-0.08), PEIX: 12.03 (-0.41), BCLI: 4.14 (+0.02), MIG: 8.54 (unch), NDRM: 13.61 (-0.14)
Spot the Potential Winners: Research Reports on SEACOR, Shanda Games, Neuroderm, Seadrill, and Lockheed Martin
PR Newswire - Wed Dec 31, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including SEACOR (NYSE: CKH), Shanda Games (NASDAQ: GAME), Neuroderm (NASDAQ: NDRM) Seadrill (NYSE: SDRL), and Lockheed Martin (NYSE: LMT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
LMT: 195.37 (-1.83), CKH: 70.12 (-4.76), GAME: 6.85 (-0.01), SDRL: 11.39 (-0.26), NDRM: 13.61 (-0.14)
NeuroDerm net loss improves in Q4 and FY14
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 6:39AM CDT
NDRM: 13.61 (-0.14)
NeuroDerm reports Q4 results
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 6:05AM CDT
NDRM: 13.61 (-0.14)
NeuroDerm Announces Fourth Quarter and 2014 Fiscal Year Financial Results and Provides a Corporate Update
GlobeNewswire - Thu Apr 02, 6:00AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.
NDRM: 13.61 (-0.14)
NeuroDerm to Announce Updated Topline Results of Phase II Study of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease at the 67th Annual Meeting of the American Academy of Neurology
GlobeNewswire - Wed Apr 01, 6:00AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that updated results from the Phase II Study assessing the safety, tolerability and pharmacokinetics (PK) of ND0612L will be presented at the American Academy of Neurology (AAN) 67 Annual Meeting taking place April 18 to 25, 2015 in Washington, DC.
NDRM: 13.61 (-0.14)
New Parkinson's drug cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 9:23AM CST
ADMS: 17.70 (-0.03), ACOR: 33.12 (-0.38), NDRM: 13.61 (-0.14), XNPT: 7.36 (-0.14), IPXL: 49.55 (-0.53), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), PRTA: 37.35 (-0.48)
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 49.55 (-0.53), ADMS: 17.70 (-0.03), ACOR: 33.12 (-0.38), NDRM: 13.61 (-0.14)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 11:46AM CST
HTBX: 6.89 (-0.71), NES: 3.80 (-0.07), TEAR: 2.44 (-0.02), FENG: 7.27 (+0.02), OCN: 7.74 (-0.15), STX: 58.34 (-0.41), LACO: 8.70 (unch), PHMD: 2.05 (+0.09), BBEP: 6.23 (-0.06), HGSH: 3.28 (+0.05), MBT: 11.97 (+0.18), NBG: 1.23 (+0.06), NDRM: 13.61 (-0.14), PT: 0.66 (-0.03), POST: 47.60 (-0.58), ATNM: 2.95 (-0.08), MWV: 47.50 (+0.41), WRES: 1.14 (-0.02), IDN: 1.63 (unch), KONE: 5.49 (+0.86)
NeuroDerm Announces Extraordinary General Meeting of Shareholders for Ratification of Election of External Directors and Adoption of Compensation Policy
GlobeNewswire - Mon Jan 19, 10:15AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will hold an Extraordinary General Meeting of Shareholders on Monday, February 23, 2015 for the purposes of ratifying the election of the Company's external directors, Alla Felder and Jonathan Kalman, and adopting a compensation policy for the Company's executives and directors. The record date for shareholders entitled to vote at the meeting is Friday, January 23, 2015.
NDRM: 13.61 (-0.14)
Securities Lending Notable Names: JCP, AMBA
Interactive Brokers - at Seeking Alpha - Tue Jan 13, 2:32AM CST
Strong sales guidance gave some life to struggling department store operator, J.C. Penney Co., Inc. (NYSE: JCP ) last week following a prolonged period of negative news. The stock soared approximately 17% on Tuesday of last week after the company...
AMBA: 72.13 (-1.32), GPRO: 44.73 (-1.35), EDAP: 3.30 (-0.07), LNCO: 12.13 (-0.24), IMRS: 0.69 (+0.04), GALT: 3.29 (-0.04), JCP: 8.41 (-0.07), MOC: 1.92 (+0.02), BIND: 6.84 (-0.33), LINE: 13.56 (-0.05), JOB: 0.83 (+0.01), BCLI: 4.14 (+0.02), NDRM: 13.61 (-0.14)
NeuroDerm Ltd. (NDRM) in Focus: Stock Surges 13.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 8:11AM CST
NeuroDerm Ltd. (NDRM) was a big mover last session, as the company saw its shares rise over 13% on the day.
BIOD: 1.14 (-0.13), NDRM: 13.61 (-0.14)
NeuroDerm (NDRM) in Focus: Stock Tanks 22.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 7:40AM CST
Make sure to keep a close watch on NeuroDerm in the near future, and especially on earnings estimates following the recent slump.
NDRM: 13.61 (-0.14)
NeuroDerm set for modest gap up at the open
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 7:38AM CST
NDRM: 13.61 (-0.14)
NeuroDerm Skyrockets on Parkinson's Disease Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 2:50PM CST
NeuroDerm (NDRM) announced encouraging top-line data from a phase IIa pharmacokinetic study on its levodopa/carbidopa candidates, ND0612H and ND0612L.
IPXL: 49.55 (-0.53), ABBV: 66.07 (+1.82), NDRM: 13.61 (-0.14), NVS: 104.28 (-1.22)
Market News: Civeo Corp, Eagle Rock Energy Partners, Neuderm Ltd
at The Street - Wed Dec 31, 1:53PM CST
The stock markets in the United States fluctuated declined, wiping out earlier gains today–the last trading session for 2014. The markets were negatively impacted by the weakness of equities in ...
CVEO: 3.43 (-0.06), EROC: 2.55 (+0.03), NDRM: 13.61 (-0.14)
NeuroDerm (NDRM) Stock Plunges Today Following Tuesday's Gains
at The Street - Wed Dec 31, 1:16PM CST
Shares of NeuroDerm (NDRM) plummeted Wednesday as the stock sold off one day after it soared following the company's announcement of encouraging trial results for a treatment of Parkinson's disease.
NDRM: 13.61 (-0.14)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 8:15AM CST
CYTK: 7.25 (-0.18), NEON: 4.56 (-0.16), ARWR: 7.28 (+0.05), NRX: 8.26 (-0.08), PEIX: 12.03 (-0.41), BCLI: 4.14 (+0.02), MIG: 8.54 (unch), NDRM: 13.61 (-0.14)
Spot the Potential Winners: Research Reports on SEACOR, Shanda Games, Neuroderm, Seadrill, and Lockheed Martin
PR Newswire - Wed Dec 31, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including SEACOR (NYSE: CKH), Shanda Games (NASDAQ: GAME), Neuroderm (NASDAQ: NDRM) Seadrill (NYSE: SDRL), and Lockheed Martin (NYSE: LMT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
LMT: 195.37 (-1.83), CKH: 70.12 (-4.76), GAME: 6.85 (-0.01), SDRL: 11.39 (-0.26), NDRM: 13.61 (-0.14)
